BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma

Department of Pathology, University of Basel, Basel, Switzerland.
Histopathology (Impact Factor: 3.3). 01/2010; 56(2):217-28. DOI: 10.1111/j.1365-2559.2009.03462.x
Source: PubMed

ABSTRACT To clarify which immunohistochemical markers could be helpful in distinguishing between classical Hodgkin's lymphoma (cHL) and primary mediastinal B-cell lymphoma (PMBCL) to more narrowly define 'B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and cHL'.
Two hundred and 83 cHLs and 51 PMBCLs were analysed on validated tissue microarray platforms with antibodies to BOB.1, CD15, CD20, CD23, CD30, CD79a, cyclin E, LMP-1, MUM1p, p63 and Oct2. The marker cut-off scores were calculated using receiver-operating characteristic curves. Markers with the highest positive predictive value for cHL were: CD15, cyclin E, LMP-1 (all 100%), MUM1p (93%) and CD30 (83%). High sensitivity was achieved only by CD30 (92%) and cyclin E (79%). Nineteen percent of PMBCLs were also positive for CD30, which led to a lower specificity of CD30 as regards cHL (81%) compared with cyclin E (100%). The antibodies with the highest positive predictive value for PMBCL were: CD23 (98%), p63 (96%), BOB.1 (94%) and CD79a (90%), with high sensitivity for BOB.1 (100%), CD79a (89%) and p63 (82%).
The use of at least three of the most accurate immunohistochemical markers, cyclin E, CD79a and BOB.1, may be helpful in the differential diagnosis of cHL and PMBCL.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Eine krankheitsbedingte oder iatrogene Immunsuppression stellt einen erheblichen Risikofaktor dar, ein malignes Lymphom zu entwickeln. Der medizinische Fortschritt mit Organtransplantationen, erfolgreicher Behandlung von Autoimmunerkrankungen oder einer verbesserten HIV-Therapie bedingt die Zunahme immunsupprimierter Patienten. Verschiedene Formen der Immunsuppression und jeweils typische Lymphomentitäten werden im vorliegenden Artikel erörtert. Einen zweiten Schwerpunkt dieses Updates bilden Grauzonenlymphome zwischen Hodgkin-Lymphom und diffusem großzelligem B-Zell-Lymphom. Diese Kategorie stellt nicht nur ein diagnostisches Problem dar, sondern entspricht vielmehr einem biologischen Kontinuum.
    Der Pathologe 02/2013; 34(1). DOI:10.1007/s00292-012-1706-5 · 0.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Analysis of archival formalin-fixed, paraffin-embedded (FFPE) pathological specimens of three case of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) and three cases of classical Hodgkin lymphoma (CHL) revealed that hypermethylation of the BOB.1 gene promoter was exclusively observed in CHL. A discrepancy was observed, however, between the methylation status of the BOB.1 gene promoter and its expression in the EBV-positive mixed cellular CHL (MCCHL). Since MCCHL lacks the typical B-cell phenotype even in the presence of abundant BOB.1 transcription factors, functional activity of BOB.1 may be lost or reduced by a mechanism other than epigenetic gene silencing. When some tumor-suppressor gene products have lost their biological function, impact or significance of derepression of such genes may be little. Therefore, when interpreting immunohistochemical results for diagnostic or research purposes, it must be borne in mind that apparent positive immunostaining can merely be the result of chromatin remodeling and that such transient expression often has little functional significance. Any apparent positive immunohistochemical result needs to be interpreted carefully with the help of the hypermethylation status as a molecular marker of gene silencing memory.
    Acta histochemica et cytochemica official journal of the Japan Society of Histochemistry and Cytochemistry 06/2014; 47(3):125-31. DOI:10.1267/ahc.14012 · 1.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline based chemotherapy improved response rates and survival. Many centers use R-CHOP as standard treatment, but the role of the intensified regimens and consolidation radiotherapy has to be clarified. Recent data coming from retrospective analyses and an ongoing prospective study addressing the problem of consolidation radiotherapy will help to better identify risk groups and apply risk-adapted and effective treatment strategies. The latest research has helped to understand molecular mechanisms of PMBCL pathogenesis and indicated targets of directed therapy for the future.
    Current Hematologic Malignancy Reports 06/2014; 9(3). DOI:10.1007/s11899-014-0219-0
    This article is viewable in ResearchGate's enriched format